635713-04-1

Basic information

• Product Name: ETHYL N-BOC-4-(2-NITROBENZYL)PIPERIDINE-4-CARBOXYLATE
• Synonyms: ETHYL N-BOC-4-(2-NITROBENZYL)PIPERIDINE-4-CARBOXYLATE
• CAS NO: 635713-04-1
• Molecular Formula: C20H28N2O6
• Molecular Weight: 392.45
• Mol File: 635713-04-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ETHYL N-BOC-4-(2-NITROBENZYL)PIPERIDINE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL N-BOC-4-(2-NITROBENZYL)PIPERIDINE-4-CARBOXYLATE(635713-04-1)
• EPA Substance Registry System: ETHYL N-BOC-4-(2-NITROBENZYL)PIPERIDINE-4-CARBOXYLATE(635713-04-1)

Safety Data

• Hazardous Substances Data: 635713-04-1(Hazardous Substances Data)

Upstream product

• 3958-60-9 2-nitrophenylmethyl bromide 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1):

Calcitonin gene related peptide receptor antagonists

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS

The presnt invention relates to compounds of Formula (I), as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Inhibitors of prenyl-protein transferase

The present invention is directed to conformationally constrained compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.